GLP-1 Coverage Under Medicare: The Exclusion Is About the Use

Most coverage arguments in a practice are about a plan's rules. This one is not. The exclusion of weight-loss agents sits in the definition of what Part D is allowed to pay for at all, one level above any formulary, and it reaches every Part D plan and every Medicare Advantage plan with drug coverage identically. Reading it in the right order is what makes the rest of the subject tractable.

1. 01

   The Part D definition points somewhere else

   Section 1860D-2(e)(2)(A) of the Social Security Act — 42 U.S.C. 1395w-102(e)(2)(A) — provides that the term covered part D drug does not include drugs or classes of drugs, or their medical uses, which may be excluded from coverage or otherwise restricted under section 1927(d)(2) of the Act, as that section was in effect on December 8, 2003. The Part D benefit therefore does not carry its own list of excluded drugs; it borrows the Medicaid one, frozen at a date.
2. 02

   The borrowed list names the use

   Section 1927(d)(2) — 42 U.S.C. 1396r-8(d)(2) — opens by describing the following drugs or classes of drugs, or their medical uses, as ones that may be excluded from coverage or otherwise restricted. Its paragraph (A) is agents when used for anorexia, weight loss, or weight gain. Every operative word there is about the purpose of the prescription rather than the identity of the product.
3. 03

   The regulation restates both halves

   42 CFR 423.100's definition of Part D drug covers the listed drug and biological categories only where they are used for a medically accepted indication, and then excludes, at paragraph (2)(ii) of the definition, drugs or classes of drugs, or their medical uses, which may be excluded or otherwise restricted under Medicaid under sections 1927(d)(2) or (d)(3) of the Act, except for smoking cessation agents.

CMS has read the exclusion this way since Part D began in 2006, and said so in rulemaking: a drug when used for weight loss, even when not used for cosmetic purposes, is excluded from the definition of covered part D drug. The reading is not uniform across the paragraph, either. CMS's longstanding interpretation of the same paragraph's reference to weight gain has not swept in drugs used to treat AIDS wasting and cachexia — a reminder that these are interpretations of a phrase, published in the Federal Register, rather than a fixed list of products.

The sentence that resolves most confusion in this category sits in the same statutory subsection as the exclusion. After listing the drug and biological categories that make up a covered part D drug, section 1860D-2(e)(1) closes by providing that the term includes any use of a covered part D drug for a medically accepted indication. So the benefit is defined use by use in both directions: one use is excluded, and another use of the identical product is included.

Medically accepted indication

Defined for Part D at section 1860D-2(e)(4) of the Act, which adopts the meaning at section 1927(k)(6) for drugs generally and a separate anticancer-regimen rule for chemotherapy. In substance it covers a use approved under the Food, Drug, and Cosmetic Act and a use supported by a citation in one of the drug compendia the statute recognizes, which is why an indication can be accepted without appearing on the label.

The compendia

The recognized compendia are identified by statute at section 1927(g)(1)(B)(i) and carried into the Part D manual. Their significance here is procedural rather than clinical: a use with compendial support is a medically accepted indication, and a medically accepted indication that is not weight management is not reached by the weight-loss exclusion.

What the exclusion is not

It is not a prior authorization rule, a step therapy requirement, or a formulary tier. Those are utilization tools a plan applies to drugs it covers, and they are the subject of prior authorization for medications. This is a benefit-category question that is settled before any of them apply.

CMS applied that reading to this drug class directly in guidance issued to plans in March 2024, and then described the result in the CY2026 proposed rule: an anti-obesity medication that receives FDA approval for an additional indication other than chronic weight management can be considered a Part D drug for that specific use, because the use is a medically accepted indication that is not excluded. The consequence stated in the same passage is the operative one for a practice — under current policy these drugs are coverable under Part D only where the prescription is for another condition for which the drug has an FDA-approved indication or compendial support.

In December 2024 CMS proposed to change this. The proposal was to reinterpret section 1927(d)(2)(A) so that drugs used for weight loss or chronic weight management for the treatment of obesity would no longer be excluded from the definition of Part D drug, with a parallel application to Medicaid. It ran to a full regulatory-impact analysis and drew a very large comment volume, and it is the source most secondary writing on this subject is still describing.

The practical reading is short. The definition of a covered part D drug is the same today as it was before the proposal, the exclusion of weight-loss use is intact, and the indication hinge described above is still the whole of the coverage question inside Part D.

On July 1, 2026 CMS began a time-limited demonstration, the Medicare GLP-1 Bridge, which furnishes certain GLP-1 drugs for weight management to eligible Part D beneficiaries through December 31, 2027. It is a real change in what a beneficiary can obtain, and it is not a change to the Part D benefit — the distinction is structural, and it is the reason the demonstration could start without any amendment to the definition of a Part D drug.

• It runs on demonstration authority, not rulemaking. CMS cites section 402(a)(1)(A) of the Social Security Amendments of 1967, made applicable to Part D by section 1860D-42(b) of the Act — the authority to test whether changes in methods of payment or reimbursement would increase the efficiency and economy of covered health services.
• It operates outside the Part D benefit's coverage and payment flow. Part D sponsors carry no risk for the drugs furnished under it and do not opt in, and CMS uses a single central processor to handle prior authorization, claims adjudication, and payment to pharmacies.
• Because it sits outside the benefit, the Part D benefit's own machinery does not attach: the Part D deductible does not apply to it, the beneficiary's payment under it does not count toward true out-of-pocket costs, and the low-income subsidy does not apply.
• It is the primary payer for what it furnishes and does not coordinate benefits with other payers, and manufacturer coupons and discount programs may not be applied to its claims.
• Its claims are submitted electronically under the NCPDP telecommunication standard; the central processor does not take paper claims or direct member reimbursement.

A second initiative sits alongside it. The CMS Innovation Center's BALANCE model, announced under section 1115A of the Act, is a voluntary model under which CMS negotiates GLP-1 pricing and coverage terms with manufacturers on behalf of state Medicaid agencies and Part D sponsors. Its Medicare side is not launching in 2027, which is the stated reason the demonstration was extended through the end of that year. Both are worth tracking as program facts; neither alters the statutory exclusion.

Everything above is federal and stable enough to rely on. Everything that decides an individual prescription is not, and this page deliberately publishes none of it — no clinical criteria, no product list, no plan-type list, and no cost-sharing figure. Those are set by CMS or by the plan, they are revised on their own schedules, and a value that is approximately right is wrong in a matter decided by a point-of-sale rejection.

1. 01

   Settle the indication first

   Before any plan document is opened, establish which indication the prescription is written for. That answer determines whether the question is a Part D coverage question at all, and it is the one input none of the sources below can supply.
2. 02

   Then the plan's own formulary and coverage rules

   Where the use is a covered one, the ordinary Part D machinery applies — formulary placement, utilization tools, and the plan's coverage determination and exceptions process. The mechanics of a drug request, and the difference between a prior authorization and a formulary exception, are in prior authorization for medications, and the Medicare Advantage variant in prior authorization under Medicare Advantage.
3. 03

   Then the demonstration's own pages, for the demonstration

   The eligible products, the clinical criteria, the eligible plan types, the prior authorization form and the cost-sharing amount are all published and maintained by CMS, and CMS states that the product list may be updated during the demonstration. They are read there, at the date they are needed, and not carried forward from anywhere else.
4. 04

   Confirm the plan before assuming any of it

   Whether a beneficiary is in a standalone drug plan or a Medicare Advantage plan with drug coverage changes which document governs. Confirming plan type is part of routine eligibility verification, and the eligibility verification checklist covers what to capture while the patient is still in front of you.

When a claim for an excluded use is refused, the refusal is a statement that the use is not a benefit rather than a judgment about the patient. That distinction governs what can be done next, and the general form of it — including who bears the balance and when a refusal is worth challenging as a misadjudication — is the non-covered service denial. Whether an appeal is the right response at all belongs to appealing a denial. The rest of the Medicare cluster, including how the parts divide drug coverage between them, is indexed on the Medicare billing pillar.